EN
SV
About Us
Overview
Vision, mission, values
Our strategy
Executive Team
Board of Directors
Our history
Our Science
Overview
Ion channels
Publications/presentations
Partnerships & spinouts
The discovery process
Our Pipeline
Overview
Tesofensine
Tesomet
SAN711
SAN903
SAN2219
SAN2355
SAN2465
The development process
Patients & Caregivers
Overview
Hypothalamic obesity
Prader-Willi syndrome
Epilepsy
Rare diseases
Investor Relations
Overview
The Share
Financial Calendar
Financial reports and filings
Analyst Coverage
Events and Presentations
FAQs
Corporate governance
Newsroom
Overview
Press Releases
Voices
Media Kit
Join Us
Overview
Working with us
Current Openings
EN
SV
AKTIEINFO INVESTORARRANGEMENT – COPENHAGEN
Feb 29, 2024
| Uncategorized
SWISS NORDIC BIO 2024 – ZURICH, SWITZERLAND
Feb 29, 2024
| Uncategorized
BIO-EUROPE SPRING 2024 – BARCELONA
Feb 29, 2024
| Uncategorized
Redeye interview with our CSO Karin S. Nielsen
Jan 8, 2024
| Uncategorized
Redeye interview with our CEO Thomas Feldthus
Dec 19, 2023
| Uncategorized
« Older Entries
Search
Search for:
Recent Comments
Recent Comments